---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-005455"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2023-02-17T23:59:59+00:00"
generated_at: "2026-06-19T08:03:06.924705+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PAVmed subsidiary terminates MSA with ResearchDx, saves $2.725M; settles EF Hutton lawsuit for $450k

## Summary
- Lucid Diagnostics terminated MSA with ResearchDx effective Feb 10, 2023; saved $2.725M vs $3.45M originally due.
- Termination payment of $725k satisfied by issuing 553,436 shares of Lucid Diagnostics common stock, no cash outlay.
- PAVmed settled EF Hutton/Benchmark litigation for $450k cash, full release of all claims related to 2020-2021 financings.

## SEC filing metadata
- accession: 0001493152-23-005455
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2023-02-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315223005455/0001493152-23-005455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315223005455/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-005455
- JSON: https://secwatch.observer/filing/0001493152-23-005455.json
- Plain text: https://secwatch.observer/filing/0001493152-23-005455.txt

## Key facts
- Material Agreements
  PAVmed Inc. terminated Management Services Agreement with ResearchDx, Inc. valued at Termination reduces earnout and management fees from $3,450,000 to $725,000, resulting in net saving (effective 2023-02-10).
  - Action: termination
  - Counterparty: ResearchDx, Inc.
  - Value: Termination reduces earnout and management fees from $3,450,000 to $725,000, resulting in net saving
  - Effective: 2023-02-10
  source text: On February 14, 2023, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ”), a majority owned subsidiary of PAVmed Inc. (the “ Company ”), and LucidDx Labs Inc. (“LucidDx Labs”), a wholly owned subsidiary of Lucid Diagnostics, entered into an agreement (the “ Termination Agreement ”) with ResearchDx, Inc. (“ RDx ”), pursuant to which the parties mutually agreed to terminate the Management Services Agreement, dated as of February 25, 2022, by and between LucidDx Labs and RDx (the “ MSA ”), without cause. The termination was effective as February 10, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315223005455/0001493152-23-005455-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.